Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats.

JOR Spine · 2021 · PMC7984001 · PMID 33778406

Europe PMC DOI

hedged sentence

0.1090

closest p · 2.2× alpha

0.1090

boldest claim

The sentences

showed a trendP = .109not close (p > 0.1)

At day 28, the abaloparatide group showed a trend toward greater BV vs vehicle (multiplicity‐adjusted P = .109; Table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.